We have two oncology conversations for you today. The first is with Dr. Saroj Niraula of the University of Manitoba, and together we discuss the necessity of randomized controlled trials for granting FDA approval of cancer drugs. The second is with Dr. Ghulam Rehman "Manni" Mohyuddin of the University of Utah on a variety of myeloma studies, including LIGHTHOUSE, OCEANS, and HORIZON.

Feasibility of RCTs: doi.org/10.1093/jncics/pkab061
RR of Alternative Treatments: doi.org/10.1002/ijc.33231
Study Time Reduction: doi.org/10.1001/jamainternmed.2018.8351

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

August 2021

4.17 RCTs for Cancer Drug Approval with Dr. Saroj Niraula & Myeloma Studies with Dr. Manni Mohyuddin

Dr Prasad currently serves as the Director of the Center for Biologics Evaluation and Resesarch (CBER) at the US FDA. The audio on this platform were posted before my FDA employment and do not necessarily represent the views of the FDA or the United States. This site will be inactive during my federal service.

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

4.17 RCTs for Cancer Drug Approval with Dr. Saroj Niraula & Myeloma Studies with Dr. Manni Mohyuddin

Plenary Session - inactive due to federal service